Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 547

1.

Novel treatment strategies for myeloproliferative neoplasms.

Bose P, Masarova L, Verstovsek S.

Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176.

PMID:
31597841
2.

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.

Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z.

PLoS One. 2019 Sep 30;14(9):e0222912. doi: 10.1371/journal.pone.0222912. eCollection 2019.

3.

Updates in the management of polycythemia vera and essential thrombocythemia.

Bose P, Verstovsek S.

Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. Review.

4.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J.

Cancer Med. 2019 Sep 10. doi: 10.1002/cam4.2545. [Epub ahead of print]

5.

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Economides MP, Verstovsek S, Pemmaraju N.

Curr Hematol Malig Rep. 2019 Aug 1. doi: 10.1007/s11899-019-00538-4. [Epub ahead of print] Review.

PMID:
31372878
6.

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S.

Blood Adv. 2019 Aug 13;3(15):2264-2271. doi: 10.1182/bloodadvances.2019000152.

7.

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR.

Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. [Epub ahead of print]

8.

The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Masarova L, Bose P, Verstovsek S.

Curr Hematol Malig Rep. 2019 Aug;14(4):310-327. doi: 10.1007/s11899-019-00527-7. Review.

PMID:
31228096
10.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.

Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H.

Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862. [Epub ahead of print]

PMID:
31125272
11.

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A.

Ann Hematol. 2019 Jul;98(7):1611-1616. doi: 10.1007/s00277-019-03708-9. Epub 2019 May 15.

PMID:
31093708
12.

Emerging drugs for essential thrombocythemia.

Masarova L, Verstovsek S.

Expert Opin Emerg Drugs. 2019 Jun;24(2):93-105. doi: 10.1080/14728214.2019.1615437. Epub 2019 May 14.

PMID:
31050912
13.

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.

Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA.

Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019 Jun 20. Review.

PMID:
31013548
14.

SOHO State of the Art Updates and Next Questions: Myelofibrosis.

Pettit K, Verstovsek S, Talpaz M.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):191-199. doi: 10.1016/j.clml.2019.03.011. Epub 2019 Mar 22. Review.

PMID:
30987952
15.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE.

Blood Adv. 2019 Mar 26;3(6):851-861. doi: 10.1182/bloodadvances.2018025874.

16.

SMAC mimetics as potential cancer therapeutics in myeloid malignancies.

Boddu P, Carter BZ, Verstovsek S, Pemmaraju N.

Br J Haematol. 2019 Apr;185(2):219-231. doi: 10.1111/bjh.15829. Epub 2019 Mar 5. Review.

PMID:
30836448
17.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597
18.

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S.

Blood. 2019 May 23;133(21):2348-2351. doi: 10.1182/blood-2019-01-897637. Epub 2019 Feb 22. No abstract available.

PMID:
30796023
19.

Myelofibrosis osteoclasts are clonal and functionally impaired.

Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z.

Blood. 2019 May 23;133(21):2320-2324. doi: 10.1182/blood-2018-10-878926. Epub 2019 Feb 11.

PMID:
30745304
20.

New Concepts of Treatment for Patients with Myelofibrosis.

Bose P, Alfayez M, Verstovsek S.

Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y. Review.

PMID:
30675650
21.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2019 Jul;60(7):1767-1774. doi: 10.1080/10428194.2018.1543876. Epub 2019 Jan 11.

PMID:
30632841
22.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.

PMID:
30575820
23.

Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.

Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S.

Acta Haematol. 2019;141(1):23-27. doi: 10.1159/000494427. Epub 2018 Nov 21.

PMID:
30463063
24.

Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.

Hu Z, Ramos CEB, Medeiros LJ, Zhao C, Yin CC, Li S, Hu S, Wang W, Thakral B, Xu J, Verstovsek S, Lin P.

Hum Pathol. 2019 Mar;85:290-298. doi: 10.1016/j.humpath.2018.10.026. Epub 2018 Nov 15.

PMID:
30447300
25.

Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.

Masarova L, Verstovsek S.

J Clin Oncol. 2018 Oct 22:JCO2018793497. doi: 10.1200/JCO.2018.79.3497. [Epub ahead of print]

PMID:
30346901
26.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F.

J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x.

27.

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.

Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G.

Leuk Res. 2018 Oct;73:78-85. doi: 10.1016/j.leukres.2018.09.004. Epub 2018 Sep 14.

28.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

PMID:
30242087
29.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

30.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.

Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.

31.

A multimodality work-up of patients with Hypereosinophilia.

Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA.

Am J Hematol. 2018 Nov;93(11):1337-1346. doi: 10.1002/ajh.25247. Epub 2018 Sep 26.

PMID:
30105844
32.

Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.

Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S.

Hematol Oncol. 2018 Oct;36(4):701-708. doi: 10.1002/hon.2544. Epub 2018 Sep 11.

33.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R.

Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Review.

34.

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.

Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z.

Br J Haematol. 2019 Apr;185(2):382-386. doi: 10.1111/bjh.15528. Epub 2018 Aug 3. No abstract available.

PMID:
30074241
35.

Patient Perceptions in Mast Cell Disorders.

Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P, Castells MC.

Immunol Allergy Clin North Am. 2018 Aug;38(3):505-525. doi: 10.1016/j.iac.2018.04.006. Review.

36.

Kit Mutations: New Insights and Diagnostic Value.

Falchi L, Verstovsek S.

Immunol Allergy Clin North Am. 2018 Aug;38(3):411-428. doi: 10.1016/j.iac.2018.04.005. Epub 2018 Jun 9. Review.

PMID:
30007460
37.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
38.

Renal complications of primary myelofibrosis.

Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A.

Leuk Lymphoma. 2019 Feb;60(2):507-510. doi: 10.1080/10428194.2018.1474525. Epub 2018 Jul 3. No abstract available.

PMID:
29966471
39.

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.

Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S.

Ann Hematol. 2018 Nov;97(11):2071-2080. doi: 10.1007/s00277-018-3402-x. Epub 2018 Jun 27.

PMID:
29951914
40.

Management of Myelofibrosis-Related Cytopenias.

Bose P, Verstovsek S.

Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Review.

PMID:
29796726
41.

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.

Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG.

Ann Oncol. 2018 Aug 1;29(8):1880-1882. doi: 10.1093/annonc/mdy173. No abstract available.

PMID:
29767670
42.

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary.

Verstovsek S.

Clin Adv Hematol Oncol. 2018 Feb;16 Suppl 4(2):20-23. No abstract available.

PMID:
29742090
43.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2019 Jan;60(1):37-48. doi: 10.1080/10428194.2018.1464158. Epub 2018 May 9.

PMID:
29741984
44.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

45.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z.

Ann Hematol. 2018 Jul;97(7):1183-1191. doi: 10.1007/s00277-018-3289-6. Epub 2018 Mar 20.

46.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
47.

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2018 Mar 15;11(1):42. doi: 10.1186/s13045-018-0585-5.

48.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S.

JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.

49.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

50.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713

Supplemental Content

Loading ...
Support Center